NEWS
February 3, 2010
Novartis completes acquisition of Corthera
December 22, 2009
Novartis to acquire Corthera Inc., gaining worldwide rights to Phase III project
relaxin for treatment of acute decompensated heart failure
October 01, 2009
Corthera’s Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure
May 28, 2009
Results and Additional Analyses From Efficacy and Safety Study of Corthera’s Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
March 29, 2009
Results From Study Show Promising Efficacy and Safety Results for Corthera’s Relaxin in Acute Heart Failure
March 23, 2009
Results From Efficacy and Safety Study of Corthera’s Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th
Annual Scientific Session
November 10, 2008
Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Corthera’s Relaxin in
Acute Heart Failure
November 03, 2008
Top-Line Preliminary Data From Phase II/III Study of Corthera’s Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008
January 08, 2008
Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
December 20, 2007
Corthera Closes $23 Million Financing Round